Savara Stock Forecast, Price & News

-0.09 (-4.41 %)
(As of 04/9/2021 12:00 AM ET)
Today's Range
Now: $1.95
50-Day Range
MA: $1.85
52-Week Range
Now: $1.95
Volume1.31 million shs
Average Volume3.95 million shs
Market Capitalization$105.76 million
P/E RatioN/A
Dividend YieldN/A
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
Savara logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SVRA
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Cash Flow$7.50 per share
Book Value$2.47 per share


Net Income$-78,170,000.00


Market Cap$105.76 million
Next Earnings Date5/6/2021 (Estimated)


2 “Strong Buy” Penny Stocks That Could Go Boom
March 30, 2021 |
Sizing Up Savara - Seeking Alpha
March 23, 2021 |
Savara (NASDAQ:SVRA) Research Coverage Started at Oppenheimer
March 22, 2021 |
Savara (NASDAQ:SVRA) Trading Down 8.6%
March 18, 2021 |
Savara Stock Rallies: Technical Analysis Levels
March 16, 2021 |
See More Headlines


Overall MarketRank

1.93 out of 5 stars

Medical Sector

79th out of 2,011 stocks

Pharmaceutical Preparations Industry

30th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -
-0.09 (-4.41 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SVRA News and Ratings via Email

Sign-up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Savara (NASDAQ:SVRA) Frequently Asked Questions

Is Savara a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Savara stock.
View analyst ratings for Savara
or view top-rated stocks.

What stocks does MarketBeat like better than Savara?

Wall Street analysts have given Savara a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Savara wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Savara?

Savara saw a increase in short interest during the month of February. As of February 26th, there was short interest totaling 904,300 shares, an increase of 23.6% from the February 11th total of 731,800 shares. Based on an average trading volume of 536,500 shares, the short-interest ratio is presently 1.7 days. Approximately 2.3% of the shares of the company are short sold.
View Savara's Short Interest

When is Savara's next earnings date?

Savara is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Savara

How were Savara's earnings last quarter?

Savara Inc (NASDAQ:SVRA) posted its earnings results on Thursday, November, 5th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.01. The firm earned $0.26 million during the quarter.
View Savara's earnings history

How has Savara's stock been impacted by COVID-19?

Savara's stock was trading at $2.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SVRA stock has decreased by 17.4% and is now trading at $1.95.
View which stocks have been most impacted by COVID-19

What price target have analysts set for SVRA?

4 Wall Street analysts have issued 12-month price objectives for Savara's stock. Their forecasts range from $3.00 to $7.00. On average, they expect Savara's share price to reach $4.67 in the next year. This suggests a possible upside of 139.3% from the stock's current price.
View analysts' price targets for Savara
or view top-rated stocks among Wall Street analysts.

Who are Savara's key executives?

Savara's management team includes the following people:
  • Robert N. Neville, Chairman of the Board, Chief Executive Officer (Age 51)
  • Taneli Jouhikainen, President, Chief Operating Officer (Age 51)
  • David L. Lowrance, Chief Financial Officer (Age 50)
  • Nevan C. Elam, Independent Director (Age 49)
  • Richard J. Hawkins, Independent Director (Age 68)
  • Joseph S. McCracken Ph.D., Independent Director (Age 64)
  • Matthew Pauls J.D., Independent Director (Age 46)
  • Yuri Pikover, Independent Director (Age 56)

Who are some of Savara's key competitors?

What other stocks do shareholders of Savara own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BioLineRx (BLRX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CEL-SCI (CVM), Geron (GERN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Verastem (VSTM), Agile Therapeutics (AGRX) and Corbus Pharmaceuticals (CRBP).

What is Savara's stock symbol?

Savara trades on the NASDAQ under the ticker symbol "SVRA."

How do I buy shares of Savara?

Shares of SVRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Savara's stock price today?

One share of SVRA stock can currently be purchased for approximately $1.95.

How much money does Savara make?

Savara has a market capitalization of $105.76 million. The company earns $-78,170,000.00 in net income (profit) each year or $4.57 on an earnings per share basis.

What is Savara's official website?

The official website for Savara is

Where are Savara's headquarters?

Savara is headquartered at 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746.

How can I contact Savara?

Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746. The company can be reached via phone at 512-614-1848 or via email at [email protected]

This page was last updated on 4/11/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.